Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Overdose Response topic
No spam. Unsubscribe anytime.
San Francisco reports sharp drop in overdose deaths; health officials point to expanded treatment and naloxone outreach
Summary
The Department of Public Health told the Health Commission that August 2024 overdose deaths fell nearly 50% from August 2023 and that expanded access to medications and naloxone distribution likely played a role; officials said the data are preliminary and pledged further analysis tying specific interventions to outcomes.
The San Francisco Department of Public Health reported a steep month-over-month decline in overdose deaths to the Health Commission on Sept. 17, with August 2024 deaths described as "down nearly 50%" compared with August 2023 and the first eight months of 2024 down about 20% from the same period in 2023.
Director of Health Dr. Grant Colfax told commissioners that the city has "redoubled our efforts" across behavioral health and street teams to expand access to life-saving medications, including methadone and buprenorphine, and that these efforts correlate with increased treatment-seeking and fewer deaths. "We continue to have a major overdose epidemic largely driven by fentanyl," Colfax said, but added, "we're starting to see declines in overdose deaths. We hope this trend continues."
Colfax and other presenters emphasized naloxone distribution as part of that response. When Commissioner Chao asked about naloxone’s role, Colfax said the department has distributed "tens of thousands of kits, including in SROs," and that naloxone provision is now standard across clinical providers and contractors. Pharmacy leadership later noted the network obtained more than 55,000 free naloxone doses from the state and estimated a roughly $1.4 million savings to the city from those shipments.
Health officials cautioned the numbers are preliminary. Colfax observed that the medical examiner updates and revises counts and promised a follow-up presentation that will present longer-term trends and link specific interventions — for example, expanded methadone access or street-team treatment offers — with observed changes in mortality. Commissioner Christian asked the department to present visually what each major intervention contributed to the trend so commissioners and the public can assess which measures had the most impact; Colfax agreed to provide that analysis in a future briefing.
Why it matters: San Francisco’s reported drop in overdose deaths could reflect the city’s expanded treatment and harm-reduction work, but officials and commissioners stressed the need for more granular, validated data before drawing causal conclusions. The department said it will return with a more detailed, intervention-linked presentation in the coming months.
What’s next: The department will provide commissioners with additional detail on naloxone distribution and a visual, longitudinal presentation tying program rollouts to changes in overdose deaths. The numbers reported to the commission remain subject to medical-examiner revisions.
